Seeing Is Believing
CTNM is currently covered by 3 analysts with an average price target of $19.83. This is a potential upside of $8.22 (57.88%) from yesterday's end of day stock price of $12.56.
Contineum Therapeutics, Common Stock's activity chart (see below) currently has 20 price targets and 21 ratings on display. The stock rating distribution of CTNM is 100% BUY.
Analysts average stock forecasts to be materialized ratio is 13.33% with an average time for these price targets to be met of 63.89 days.
Highest price target for CTNM is $24, Lowest price target is $14, average price target is $19.83.
Most recent stock forecast was given by DEBANJANA CHATTERJEE from JONESTRADING on 15-Sep-2026. First documented stock forecast 30-Apr-2024.
Currently out of the existing stock ratings of CTNM, 5 are a BUY (100%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 13-Mar-2025
$24
$11.44 (91.08%)
$23
13 days ago
(15-Sep-2026)
0/2 (0%)
$10.18 (73.66%)
Buy Since 30-Apr-2024
$23
$10.44 (83.12%)
$22
1 months 28 days ago
(31-Jul-2026)
0/8 (0%)
$7.51 (48.48%)
Hold Since 14-May-2026
$16
$1.81 (12.76%)
$14
4 months 14 days ago
(14-May-2026)
1/5 (20%)
$1.79 (12.60%)
19
Buy Since 22-Oct-2024
$20
$5.81 (40.94%)
$16
6 months 22 days ago
(06-Mar-2026)
1/3 (33.33%)
$6.12 (44.09%)
349
Buy Since 30-Apr-2024
$29
$16.44 (130.89%)
$29
2 years 1 months 13 days ago
(15-Aug-2024)
0/2 (0%)
$10.41 (56.00%)
What is CTNM (Contineum Therapeutics, Common Stock) average time for price targets to be met?
Which analyst most recently updated their price target on CTNM (Contineum Therapeutics, Common Stock)?
Which analyst has the current lower performing score on CTNM (Contineum Therapeutics, Common Stock) with a proven track record?
Which analyst has the most public recommendations on CTNM (Contineum Therapeutics, Common Stock)?
Which analyst is the currently most bullish on CTNM (Contineum Therapeutics, Common Stock)?
Which analyst is the currently most reserved on CTNM (Contineum Therapeutics, Common Stock)?